Clindamycin Phosphate and Benzoyl Peroxide NDC 72162-2077

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2077Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2077Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2077-1	72162207701	1 BOTTLE, PUMP in 1 CARTON (72162-2077-1) / 50 g in 1 BOTTLE, PUMPMarketed from Aug 16, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clindamycin Phosphate and Benzoyl Peroxide
Generic name (nonproprietary): clindamycin phosphate, benzoyl peroxide
Active ingredients: Benzoyl peroxide — 25 mg/gClindamycin phosphate — 10 mg/g
Dosage form: Gel
Route: Topical
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205397
Marketing start: Sep 12, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Sebaceous Gland Activity (Physiologic effect)Lincosamides (Chemical structure)Neuromuscular Blockade (Physiologic effect)
Identifiers: Product ID 72162-2077_1ce2692a-4384-4f6c-9de3-491692751388SPL ID 1ce2692a-4384-4f6c-9de3-491692751388SPL set ID 4e09c0e6-7da1-462c-9f1f-64c18e5f58f9RxCUI 885131UNII W9WZN9A0GM, EH6D7113I8
Pharmacologic class: Lincosamide Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162207701 followed by a unit qualifier and the quantity

Package 72162-2077-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 18, 2024.

Indications (excerpt from the label)

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is indicated for the topical treatment of acne vulgaris in patients 12 years or older. Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205397

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205397
Product	Strength	Form · route	Labeler	Product NDC
Clindamycin Phosphate and Benzoyl Peroxideclindamycin phosphate, benzoyl peroxide	Benzoyl peroxide 25 mg/g; Clindamycin phosphate 10 mg/g	GelTopical	Bryant Ranch Prepack	63629-8635
Clindamycin Phosphate and Benzoyl Peroxideclindamycin phosphate, benzoyl peroxide	Benzoyl peroxide 25 mg/g; Clindamycin phosphate 10 mg/g	GelTopical	Padagis Israel Pharmaceuticals Ltd	45802-597